What is NDC 0409-2337?

0409-2337 is the product NDC for Deferoxamine Mesylate, Deferoxamine mesylate 2 g/1 injection, powder, lyophilized, for solution, listed with the FDA by Hospira, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.

Hospira, Inc., NDC labeler code 0409. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Deferoxamine Mesylate?

4 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Deferoxamine Mesylate NDC 0409-2337 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)0409-2337Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00409-2337Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0409-2337-25	00409233725	4 VIAL, SINGLE-USE in 1 CARTON (0409-2337-25) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-USE (0409-2337-15)Marketed from Mar 31, 2005

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Deferoxamine Mesylate
Generic name (nonproprietary): deferoxamine mesylate
Active ingredients: Deferoxamine mesylate — 2 g/1
Dosage form: Injection, Powder, Lyophilized, For solution
Route: Intramuscular, Intravenous, Subcutaneous
Labeler: Hospira, Inc.NDC labeler code 0409
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 076019
Marketing start: Mar 31, 2005
Listing expires: Dec 31, 2027
Other FDA classes: Iron Chelating Activity (Mechanism)
Identifiers: Product ID 0409-2337_0c19b646-2901-4648-a502-a226b1eb0fefSPL ID 0c19b646-2901-4648-a502-a226b1eb0fefSPL set ID f9ab6b1c-98d0-4373-0e9b-b10cb4a67543RxCUI 1731345, 1731350UNII V9TKO7EO6K
Pharmacologic class: Iron Chelator

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N400409233725 followed by a unit qualifier and the quantity

Package 00409-2337-25. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 6, 2026.

Indications (excerpt from the label)

Deferoxamine mesylate for injection is an iron-chelating agent indicated: • As an adjunct to standard measures for the treatment of acute iron intoxication. ( 1.1 ) • For the treatment of transfusional iron overload in patients with chronic anemia. ( 1.2 ) Limitations of Use Deferoxamine mesylate for injection is not indicated for the treatment of primary hemochromatosis (since phlebotomy is the method of choice for removing excess iron in this disorder). 1.1 Acute Iron Intoxication Deferoxamine Mesylate for injection is indicated as an adjunct to standard measures for the treatment of acute iron intoxication. 1.2 Chronic Iron Overload Deferoxamine Mesylate for injection is indicated for the…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 0409-2337

What is NDC 0409-2337?: 0409-2337 is the product NDC for Deferoxamine Mesylate, Deferoxamine mesylate 2 g/1 injection, powder, lyophilized, for solution, listed with the FDA by Hospira, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Deferoxamine Mesylate.
What is the active ingredient?: Deferoxamine mesylate.
Who is the labeler?: Hospira, Inc., NDC labeler code 0409. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Deferoxamine Mesylate?: 4 other product NDCs are listed under this name. See all Deferoxamine Mesylate NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Deferoxamine Mesylate NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Deferoxamine mesylate	Deferoxamine mesylate 500 mg/1	Injection, Powder, Lyophilized, For solutionIntramuscular, Intravenous, Subcutaneous	Apotex Corp.	60505-6236	60505-6236-06
Deferoxamine mesylate	Deferoxamine mesylate 2 g/1	Injection, Powder, Lyophilized, For solutionIntramuscular, Intravenous	Apotex Corp.	60505-6237	60505-6237-06
Deferoxamine mesylate	Deferoxamine mesylate 500 mg/1	Injection, Powder, Lyophilized, For solutionIntramuscular, Intravenous, Subcutaneous	Gland Pharma Limited	68083-172	68083-0172-01
Deferoxamine mesylate	Deferoxamine mesylate 2 g/1	Injection, Powder, Lyophilized, For solutionIntramuscular, Intravenous, Subcutaneous	Gland Pharma Limited	68083-173	68083-0173-01